Comparison between Bio Medica Laboratories IPO and Natrinai Ventures IPO.
Bio Medica Laboratories IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Natrinai Ventures IPO is a SME Bookbuilding proposed to list at BSE SME.
The total issue size of Bio Medica Laboratories IPO is up to ₹0.00 Cr whereas the issue size of the Natrinai Ventures IPO is up to ₹0.00 Cr. The final issue price of Bio Medica Laboratories IPO is and of Natrinai Ventures IPO is .
| Bio Medica Laboratories IPO | Natrinai Ventures IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 32,05,200 shares | 41,40,000 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 3,76,800 shares | 2,20,200 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 35,82,000 shares | 43,60,200 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
Bio Medica Laboratories IPO opens on , while Natrinai Ventures IPO opens on . The closing date of Bio Medica Laboratories IPO and Natrinai Ventures IPO is , and , respectively.
Bio Medica Laboratories IPO P/E ratio is , as compared to Natrinai Ventures IPO P/E ratio of .
| Bio Medica Laboratories IPO | Natrinai Ventures IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Bio Medica Laboratories Ltd.'s revenue increased by 150% and profit after tax (PAT) rose by 292% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Standalone)Natrinai Ventures Ltd.'s revenue increased by 42% and profit after tax (PAT) rose by 151% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 99.99 | 99.98 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 99.59 | 92.02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 48.20 | 81.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.02 | 0.54 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 99.59 | 63.02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Bio Medica Laboratories IPO Retail Individual Investors (RII) are offered 0 shares while in Natrinai Ventures IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Bio Medica Laboratories IPO and 0 shares in Natrinai Ventures IPO.
| Bio Medica Laboratories IPO | Natrinai Ventures IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 1,89,600 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
Bio Medica Laboratories IPO subscribed in total, whereas Natrinai Ventures IPO subscribed .
